Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have not yet extended to all patients or all cancer types. Ovarian cancer is one such example.
MD Anderson’s Ovarian Cancer Moon Shot® seeks to change this by exploring the use of immunotherapy to bring lasting results to more patients.
Amir Jazaeri, M.D., professor of Gynecologic Oncology...
President Donald Trump today announced his intent to appoint Hussein Tawbi, M.D., Ph.D., associate professor and deputy chairman of Melanoma...
Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...
Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.
This month, MD Anderson finalized an asset purchase agreement with Bellicum...
Researchers from MD Anderson have revealed how glioma cells move and infiltrate the brain, providing a new potential treatment pathway to...
A study published in JAMA comparing adverse event outcomes by treatment type for patients with localized prostate cancer reveals most...
MD Anderson has created a new research platform to drive the discovery of new therapeutic agents for patients with leukemia by investigating...